Nicox Funding: How Much Did They Raise & Key Investors

How Much Did Nicox Raise?
Funding & Key Investors

Nicox, a prominent international player in the ophthalmology sector, has successfully navigated multiple capital-raising cycles to bolster its research and development pipeline. With a cumulative capital infusion reaching $58.7M, the firm continues to solidify its market presence through strategic share placements. The most recent financing round, totaling $0, underscores the ongoing investor confidence in the company's ability to deliver innovative ocular health solutions on a global scale.

This latest injection of capital serves as a critical milestone for the Sophia Antipolis-based organization, enabling the continued advancement of its proprietary therapeutic portfolio. By maintaining a disciplined approach to financial growth, Nicox remains well-positioned to address the unmet needs of patients suffering from chronic ocular conditions, including glaucoma and allergic conjunctivitis.

What is Nicox?

Nicox

Manufacturing

Pharmaceuticals

Business Services

Founded in 1996, Nicox operates as a specialized pharmaceutical entity dedicated to the research, development, and commercialization of vision-maintenance therapies. The company's business model centers on high-impact ocular health innovation, exemplified by its flagship products such as VYZULTA and ZERVIATE. By leveraging a robust R&D framework, Nicox has successfully licensed its treatments to global partners, effectively extending its reach across European and North American markets. As a publicly traded entity on Euronext Paris, the company is recognized for its scientific rigor and its strategic focus on addressing complex conditions like ocular hypertension and dry eye disease, positioning itself as a vital contributor to the global ophthalmology landscape.

How much funding has Nicox raised?

Nicox has raised a total of $58.7M across 4 funding rounds:

2019

Share Placement

$13.6M

2020

Share Placement

$18.2M

2021

Share Placement

$16.9M

2022

Share Placement

$10M

Share Placement (2019): $13.6M with participation from Undisclosed

Share Placement (2020): $18.2M led by HBM Healthcare Investments

Share Placement (2021): $16.9M, investors not publicly disclosed

Share Placement (2022): $10M, investors not publicly disclosed

Key Investors in Nicox

HBM Healthcare Investments

HBM Healthcare Investments is a publicly traded investment firm that focuses on the global healthcare sector, managing a diversified portfolio of both private and public companies to capture growth from medical advancements.

Undisclosed Investors

What's next for Nicox?

Looking ahead, Nicox is poised to leverage its recent capital influx to accelerate the clinical development of its next-generation ocular therapies. The company's strategic roadmap emphasizes the expansion of its commercial footprint and the optimization of its existing product portfolio through targeted research initiatives. By focusing on high-growth segments within the ophthalmology market, Nicox aims to enhance shareholder value while addressing the evolving demands of the global healthcare sector. Future growth will likely be driven by the successful execution of its licensing strategy and the continued validation of its innovative pipeline in key international markets.

See full Nicox company page

See More Financial Insights